Onvansertib in Combination With NALIRIFOX for First Line Treatment of Advanced Pancreatic Cancer
Onvansertib in Combination With NALIRIFOX for First Line Treatment of Advanced Pancreatic Cancer
Active, not recruiting · NCT06736717 · Registry updated 2026-09-25Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Onvansertib in Combination With NALIRIFOX for First Line Treatment of Advanced Pancreatic Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, endocrine system disorder, malignant endocrine neoplasm, malignant pancreatic neoplasm, neoplasm, pancreas disorder, pancreatic neoplasm | Active, not recruiting | Phase 1 / Phase 2 | 2026-09-25 | NCT06736717 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Cardiff Oncology | 5 |
| University of Kansas Medical Center | 169 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| The University of Kansas Cancer Center, Westwood Campus | Kansas City | United States | 6 |